Clinical Trial Update: Rigosertib for RDEB-SCC [Phase 1, Phase 2]

View source ↗

Summary

Completed Phase 1/2 clinical trial evaluating rigosertib for squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Recessive Dystrophic Epidermolysis Bullosa
• Squamous Cell Carcinoma

Drugs mentioned

• Rigosertib (rigosertib)

Snippet

Sponsor: Prof. Johann Bauer | Conditions: Epidermolysis Bullosa Dystrophica, Squamous Cell Carcinoma | Phase 1, Phase 2 | Status: COMPLETED